Jeffrey Leiden is leaving Vertex Pharma after seven years as president and CEO, to be replaced by chief medical officer Reshma Kewalramani. Leiden isn’t heading off into the sunset, however.

On an investor call late Wednesday, Vertex executive chairman and former CEO Jeffrey Leiden called povetacicept a “potential best-in-class medicine.” Wall Street analysts, however, noted that ...

In May 2022, Vertex opened the 270,000-square-foot Jeffrey Leiden Center for Cell and Genetic Therapies at the corner of ...

Vertex's Jeffrey Leiden Vertex’s CEO, Jeffrey Leiden, said: “This approval is an important milestone in our journey to treat every person with CF, and we remain committed to urgently advancing ...